Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05467670
Title Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Haider Mahdi

ovary epithelial cancer


Doxorubicin + Evorpacept + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.